Abbott to Develop and Commercialise Biotest’s BT-061 for Autoimmune Diseases
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)
Published: 27 Jun-2011
DOI: 10.3833/pdr.v2011.i6.1486 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Abbott has licensed exclusive global rights to Biotest’s BT-061, a novel humanised anti-CD4 antibody in Phase II development for rheumatoid arthritis and psoriasis that could become a successor to Humira® (adalimumab)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS